found that the synergistic combination of shikonin and the suppressor of PD-L1 (JQ1) as well as the treatment potency of the PD-L1 checkpoint blockage mannosylated lactoferrin nanoparticulate system could reprogram the tumor immune microenvironment and metabolism via tumor-associated macrophages and glucose metabolism (32). This evidence concerns the gene CD274 and neoplasm.